EMA letters reveal extent of Abbvie/InterMune data disclosure concerns
This article was originally published in SRA
Executive Summary
In trying to prevent the European Medicines Agency from releasing clinical trial data on its blockbuster product Humira (adalimumab), Abbvie is claiming not only that the documents in question are commercially confidential, but that releasing them would be a breach of copyright law1,2.